Bristol-Myers Squibb Co., of Princeton, said its randomized, blinded comparative phase III study testing PD-1 inhibitor nivolumab vs. dacarbazine (DTIC) in patients with previously untreated BRAF wild-type advanced melanoma was stopped early because an analysis conducted by the independent data monitoring committee showed evidence of superior overall survival in patients receiving the drug vs. those in the control arm.